Mega Genomics Limited disclosed that it repurchased 94,200 ordinary shares on 25 September 2026 through on-exchange transactions at a volume-weighted average price of HKD 6.99 per share. The total outlay amounted to HKD 658,793.

Following the transaction, issued shares (excluding treasury shares) declined by 0.0423% to 222.40 million, while treasury shares increased to 1.90 million. The company’s total issued share count remains unchanged at 224.30 million.

The buyback was executed under the mandate granted by shareholders on 21 May 2026, which authorised the repurchase of up to 22.43 million shares. Cumulative repurchases since the mandate now stand at 1.90 million shares, equivalent to 0.85% of the issued share base on the mandate date.

A 30-day moratorium on new share issues or treasury share disposals applies until 25 October 2026 in accordance with Hong Kong Stock Exchange rules.